Centro di Riferimento Oncologico - Aviano — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Centro di Riferimento Oncologico - Aviano appears in 27 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials27

Recruiting shown13

Roles2

SourceClinicalTrials.gov

Clinical trials

27 shown

Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial CancerNCT07397624 · lead sponsor · 2026-01-08

Prostate Cancer REsearch Using Cross-validation of Innovative Sampling, Integrating LC-MS/MS for Optimized Therapeutic Drug moNitoringNCT07344363 · lead sponsor · 2025-11-19

Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer PatientsNCT07539038 · lead sponsor · 2025-04-03

Precision Retrospective Integrative Study for Metastatic Lymph Nodes in Breast CancerNCT06738459 · lead sponsor · 2025-01-01

Effectiveness of an N-acetylcysteine and Urea-based Cream in Prevention of Capecitabine-induced HAND-foot Syndrome in Breast Cancer PatientsNCT06639178 · lead sponsor · 2024-08-01

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on LorlatinibNCT06378892 · lead sponsor · 2024-03-15

Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)NCT06637345 · lead sponsor · 2024-03-15

Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D.)NCT06180005 · lead sponsor · 2024-01-06

A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)NCT06028724 · lead sponsor · 2023-05-26

Dietary Habits, Nutritional Knowledge and Physical Activity Assessment in Early Stage Breast Cancer PatientsNCT06073418 · lead sponsor · 2022-10-28

InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2NCT05835739 · lead sponsor · 2019-08-27

Permanence of Indocyanine Green in Axillary Lymph Nodes 3 Weeks After Subdermal Injection in Patients With Breast Cancer and Metastatic Lymph NodesNCT06347354 · lead sponsor · 2024-09-01

The Impact of Adverse Events, Produced by Antibodies Conjugates, on Quality of Life in Patients With Metastatic Breast Cancer: Multicentric, Observational Study (EVA).NCT06106711 · lead sponsor · 2023-11-02

Overcoming Therapy Resistance in ER+ Breast Cancer Patients: a Translational Project (OVERTuRE)NCT06129786 · lead sponsor · 2023-05-18

Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)NCT06060652 · lead sponsor · 2023-05-11

A Study to Develop Molecular Integrated Predictive Models of Breast Radio-toxicity (Precise-RTox)NCT06114589 · lead sponsor · 2022-08-25

Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?NCT04172220 · lead sponsor · 2019-10-31

Use of INnovative and Micro-INvasive TEchniques for the Early Identification of Breast Cancer Patients Benefitting From Neo-adjuvant TherapyNCT05846997 · lead sponsor · 2018-06-20

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNANCT05814224 · lead sponsor · 2018-05-22

Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- TumorsNCT02307227 · lead sponsor · 2006-04-01

Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's SarcomaNCT00003419 · lead sponsor · 1998-06-01

Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV InfectionNCT00003262 · lead sponsor · 1997-05-01

Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System LymphomaNCT00003261 · lead sponsor · 1997-05-01

Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's LymphomaNCT00002905 · lead sponsor · 1995-06-01

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · collaborator · 2023-05-01

Exogenous and Endogenous Risk Factors for Early-onset Colorectal CancerNCT05732623 · collaborator · 2022-12-05

PRO Survivorship Concerns ITANCT06080607 · collaborator · 2022-01-18

Sponsor roles

lead sponsor24

collaborator3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.